Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

A comprehensive FAQ section answers questions for common drugs, giving you a deeper understanding of how these medications work to alleviate Narcolepsy symptoms.

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Wake up and go to sleep The irony of these two narcolepsy drugs that work to normalise the sleep-wake cycle is that they have to be taken twice per night. Patients have the first dose before they ...

In addition, a single pivotal phase 3 trial is planned for patients with narcolepsy. The orphan drug designation is expected to expedite further development of XW10172 for narcolepsy. The FDA ...

The US District Court for the District of Columbia has upheld the decision by the US Food and Drug Administration (FDA) to keep Avadel Pharmaceutical’s narcolepsy drug, Lumryz (sodium oxybate ...

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse. Wakix (pitolisant ...

The global market for narcolepsy treatments currently generates approximately $2 billion annually, despite existing therapies offering only marginal benefits. Orexin agonists, the drug class to which ...

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get the Real Story Behind Every Major Earnings Report ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show. The Dublin-based company anticipates ...

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ: NASDAQ:AVDL), a company specializing in the development of transformative medicines with a market capitalization of $1.05 billion, has announced ...